Pharma Stock Roundup: Mixed Q1 for MRK, PFE, FDA Nod for Kymriah's 2nd Indication

First-quarter results of pharma bigwigs like Pfizer PFE, Merck MRKand Allergan AGNstole the limelight this week. Other than that, Novartis NVSgained FDA approval for the second indication of its CAR-T therapy, Kymriah. While AbbVie ABBVsubmitted a regulatory application in the EU for its psoriasis candidate, risankizumab, Merck’s PD-L1 inhibitor, Keytruda gained FDA’s Priority Review status for yet another label expansion application.